Apheresis CD8+CCR7+CD45RA- T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome.

Int J Mol Sci · 2026 · PMC12841578 · PMID 41596518

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients with high values of CD4 + T CM cells exhibited a trend toward improved PFS and OS curves, although the differences did not reach statistical significance ( Figure 5 A,B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Apheresis CD8&lt;sup&gt;+&lt;/sup&gt;CCR7&lt;sup&gt;+&lt;/sup&gt;CD45RA&lt;sup&gt;-&lt;/sup&gt; T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome.

The sentences

Apheresis CD8<sup>+</sup>CCR7<sup>+</sup>CD45RA<sup>-</sup> T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome.